Company: DAWN
Filing Date: 2025-02-25
Form Type: 10-K
Source: 0000950170-25-026654
Chunk: 234

Company: Day One Biopharmaceuticals, Inc.
Filing Date: 2025-02-25
Form: 10-K
Item: Item 1A
Chunk 234
---
 cause the price of our common stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance. 

The market price of our common stock is likely to be highly volatile, which could result in substantial losses for purchasers of our common stock. 

The market price of our common stock is likely to continue to be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. As a result of this volatility, you may not be able to sell your shares of common stock at or above the price paid. The market price for our common stock may be influenced by many factors, including the other risks described in this “Risk Factors” section and the following: 

•the success of our commercialization efforts for our product, OJEMDA;

99

•results of preclinical studies or clinical trials by us or those of our competitors or by existing or future collaborators or licensing partners; 

•the timing and enrollment status of our clinical trials; 

•changes in the development status of our product candidates, including variations in the level of expense related to the development of our programs or funding support by us or by existing or future collaborators or licensing partners; 

•regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to our business; 

•the success of competitive products or technologies; 

•introductions and announcements of new product candidates by us, our future collaboration partners, or our competitors, and the timing of these introductions or announcements; 

•actions taken by regulatory agencies with respect to our product candidates, clinical studies, manufacturing process or sales and marketing terms; 

•our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under existing or future arrangements or the termination or modification of any such existing or future arrangements; 

•actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us; 

•the success of our efforts to acquire or in-license additional technologies or product candidates; 

•announced or completed significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors; 

•developments or disputes concerning our intellectual property and proprietary rights; 

•the recruitment or departure of key personnel; 

•changes in the structure of healthcare payment systems; 

•actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other